Interferon alpha (IFNα) and psychiatric syndromes: A review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 4, 2002, Pages 731-746

  Schaefer, Martin ^a   Engelbrechta, Marc A ^b   Gut, Oliver ^b   Fiebich, Bernd L ^b   Bauer, Joachim ^b   Schmidt, Folkhard ^c   Grunze, Heinz ^c   Lieb, Klaus ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depression; Interferon alpha; Psychiatric disorders; Side effects; Systemic lupus erythematosus

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CYTOKINE; FLUOXETINE; NEFAZODONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEDATIVE AGENT; SERTRALINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; MENTAL DISEASE; METABOLISM; PSYCHOLOGICAL ASPECT; REVIEW; SYNDROME; BRAIN BLOOD FLOW; CLINICAL TRIAL; DEPRESSION; FRONTAL LOBE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROENDOCRINE SYSTEM; PATHOGENICITY; PSYCHOSIS; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID FUNCTION;

ANIMALS; BRAIN; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; SYNDROME;

EID: 0036016293     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00324-4     Document Type: Review

References (122)

1. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer
2. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities
3. Viral antibodies and interferon in acute psychiatric disorders
4. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration
5. The interferons. Mechanisms of action and clinical applications
6. Serum interferon in first psychotic attack
7. Alpha-interferon modifies cortical EEG activity: Dose-dependence and antagonism by naloxone
8. Human leukocyte interferon: Structural and biological relatedness to adrenocorticotropic hormone and endorphins
9. Neurophysiological effects of recombinant interferon-gamma and -alpha in man
10. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon
11. Interferon enhances the excitability of cultured neurones
12. Prediction of the depressive effects of interferon alpha therapy by the patient's initial affective state
13. Major therapeutic uses of interferons
14. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: Comparison of intravenous, intramuscular, and intraventricular delivery
15. Does the immune system communicate with the central nervous system? Interferon modifies central nervous activity
16. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex
17. Cytokine-induced sickness behavior: Where do we stand?
18. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial
19. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review
20. Side effects of alpha interferon in chronic hepatitis C
21. Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis
22. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon
23. Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected
24. SPECT and PET imaging in mood disorders
25. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro
26. Successful treatment of interferon alpha-induced mood disorder with nortriptyline
27. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Gabapentin may serve as a mood stabilizer
28. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients
29. Interferon-alpha-2a
30. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population
31. Neurological effects of recombinant human interferon
32. The treatment of chronic viral hepatitis
33. Interferon alpha for patients with clinically apparent cirrhosis due to chronic hepatitis B
34. Immune interferon in the circulation of patients with autoimmune disease
35. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
36. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life
37. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis
38. Interferon responses in schizophrenia and major depressive disorders
39. Systemic lupus erythematosus presenting with diffuse low density lesions in the cerebral white matter on computed axial tomography scans: Its implication in the pathogenesis of diffuse central nervous system lupus
40. Seizures associated with low-dose alpha-interferon
41. Suicide associated with alpha-interferon therapy for chronic viral hepatitis
42. Endocrine mediated mechanisms of fatigue during treatment with interferon-α
43. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment
44. Roles of cytokines in the neural immune interactions: Modulation of NMDA-responses by IFN-alpha
45. Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia
46. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression - A study with single photon emission computed tomography
47. Dilemmas in neuropsychiatric lupus
48. Cytokines and the brain: Implications for clinical psychiatry
49. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications
50. The role of interferon alpha in the treatment of metastatic melanoma
51. Fluoxetine treatment of depression caused by interferon-alpha
52. Short and long-term immunosuppressive effects of clozapine and haloperidol
53. Cytokines and brain function: Relevance to interferon-α induced mood and cognitive changes
54. Systemic immunologic diseases as differential diagnosis in psychiatry
55. Response to higher doses of interferon alpha-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis Interventional Therapy Group
56. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection
57. Management of patients receiving interferon beta-1b for multiple sclerosis: Report of a consensus conference
58. Effects of IFN-beta on human cerebral blood flow distribution
59. Enhancement of immobility in mouse forced swimming test by treatment with human interferon
60. Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha
61. The first case of polymyositis associated with interferon therapy
62. Neurotoxicity of interferon
63. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers
64. Excitatory amino acid neurotoxicity and neurodegenerative disease
65. The effect of interferon-alpha on the pituitary-adrenal axis
66. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease
67. Persistent neurotoxicity of systemically administered interferon-alpha
68. Depression from interferon therapy in patients with hepatitis C
69. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis
70. Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients
71. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter
72. Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man
73. A phase II study of recombinant alpha interferon in patients with recurrent or metastatic breast cancer
74. Paroxetine for the prevention of depression induced by high-dose interferon alpha
75. Naloxone blocks the interferon-alpha induced changes in hypothalamic neuronal activity
76. Acute axonal polyneuropathy during interferon alpha-2A therapy for chronic hepatitis type C
77. Side effect profile of interferon beta-1b in MS: Results of an open label trial
78. Behavioral assessment of patients treated with alpha-interferon
79. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan
80. Side effects of high-dose interferon therapy for chronic hepatitis C
81. Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders
82. Pattern of neurobehavioral deficits associated with interferon alpha therapy for leukemia
83. Reversible cognitive decline during high-dose alpha-interferon treatment
84. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group
85. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
86. Serum interferon in patients with psychosis
87. Cytokine-associated emotional and cognitivedisturbances in humans
88. Interferon decreases REM latency
89. Psychiatric complications of long-term interferon alpha therapy
90. Suicidal impulses in patients with chronic viral hepatitis C treated by alpha interferon
91. Antibrain antibodies and interferon in the serum and the cerebrospinal fluid of patients with schizophrenia
92. Serum interferon in schizophrenia
93. Central nervous system toxicity of interferon
94. A search for interferon in the CSF of chronic schizophrenic patients
95. Change in cerebral blood flow in an acute hepatitis C patient with depressive state while receiving interferon
96. Psychiatric side effects during combination treatment for chronic hepatitis C with interferon alpha and ribavirin: Comparison of psychiatric patients, drug addicts and controls
97. Adding low dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis
98. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C
99. Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients
100. Sertraline treatment of interferon-alpha-induced depressive disorder
101. Hepatitis C
102. Interferon-alpha in lupus psychosis
103. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain
104. Neurological effects of recombinant human interferon
105. The interaction between cytokines and neurotransmitters in depression and stress: Possible mechanism of antidepressant treatments
106. Manic episodes in two patients treated with interferon alpha
107. Electroencephalographic abnormalities in interferon encephalopathy: A preliminary report
108. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C
109. The effects of interferon-α on the production and action of other cytokines
110. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Study Group
111. Successful treatment of interferon-alpha-induced mood disorder with nortriptyline
112. Treatment of neurotoxic side effects of interferon-alpha with naltrexone
113. Mood and cognitive side effects of interferon-α therapy
114. Interferon-alpha can be successfully in patients with hepatitis C virus-positive chronic hepatitis who have psychiatric illness
115. Immunopathology and viral reactivation. A general theory of schizophrenia
116. Interferon alpha-2a
117. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction
118. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier
119. Corticotropin-releasing hormone1 receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice
120. Hepatitis C and depression
121. Illness, cytokines, and depression
122. Serum interferon levels in patients with systemic lupus erythematosus